Lineage Cell Therapeutics Q1 net loss $4.4M, cash $46.8M; OpRegen phase 2a enrolling

Lineage Cell Therapeutics, Inc.

2023-Q1 EPS reported -$0.03 revenue$2,386,000

Revenue $2.4M, down 54% YoY from $5.2M due to lower Roche collaboration revenue.
Net loss improved to $4.4M ($0.03/share) from $7.1M ($0.04/share) in Q1 2022.
Cash equivalents and marketable securities $46.8M; expected to fund operations into Q3 2024.
OpRegen Phase 2a for GA secondary to AMD continues enrolling; new sites expected in 2023.
OPC1 granted US patent expiring no earlier than 2040; Type B meeting with FDA planned.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.